Literature DB >> 3977334

Percutaneous absorption of minoxidil in man.

T J Franz.   

Abstract

The percutaneous absorption and excretion of 1% and 5% solutions of minoxidil labeled with carbon 14 were measured in 12 adult male subjects. These subjects were randomly assigned to the 1% and 5% minoxidil testing groups, and all received nine topical applications to a bald area on the scalp, with the radioactive solutions applied on days 1 and 9. Urinary excretion of radioactivity was low, with mean values ranging from 1.6% to 3.9% of applied dose. No radioactivity could be detected in fecal samples. Recovery of radioactivity from the skin surface and from scalp and pillowcase washes was in the range of 41% to 45% of applied dose. No adverse reactions or notable abnormalities were noted in the subjects during the study. Although minoxidil is poorly absorbed through the skin, systemic doses in the range of 2.4 to 5.4 mg/day can be anticipated if application is made to entire scalp.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3977334

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  5 in total

1.  A hairy fall: syncope resulting from topical application of minoxidil.

Authors:  S W Dubrey; J VanGriethuysen; C M B Edwards
Journal:  BMJ Case Rep       Date:  2015-09-07

2.  The bioavailability of dermatological and other topically administered drugs.

Authors:  R H Guy; A H Guy; H I Maibach; V P Shah
Journal:  Pharm Res       Date:  1986-10       Impact factor: 4.200

Review 3.  Topical minoxidil. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in alopecia areata and alopecia androgenetica.

Authors:  S P Clissold; R C Heel
Journal:  Drugs       Date:  1987-02       Impact factor: 9.546

4.  Topical minoxidil: cardiac effects in bald man.

Authors:  F H Leenen; D L Smith; W P Unger
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

5.  Infantile generalized hypertrichosis caused by topical minoxidil.

Authors:  Greice Rampon; Caroline Henkin; Paulo Ricardo Martins de Souza; Hiram Larangeira de Almeida
Journal:  An Bras Dermatol       Date:  2016 Jan-Feb       Impact factor: 1.896

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.